In restructuring roughly 40 percent of the company’s leadership, Ms. Walmsley hired people outside the company from various corporations, including Google and Novartis AG, and promoted select individuals from within, the London-based company said in an email to Bloomberg.
Ms. Walmsley said in July Glaxo must focus on developing treatments for respiratory conditions, HIV, and infectious and autoimmune disorders, as well as end or divest roughly 30 drug-development programs to spur long-term growth, according to the report.
More articles on supply chain:
6 drug, devicemakers in the headlines
Kick-start your supply chain in 2018: 3 New Year’s Resolutions
Drug charity stops financial assistance services following HHS scrutiny
